Pemetrexed (Alimta)

Pemetrexed, marketed under the brand name Alimta, is an antifolate chemotherapy drug that has been the cornerstone of mesothelioma treatment since its FDA approval in February 2004. It is the only chemotherapy agent specifically approved by the U.S. Food and Drug Administration for the treatment of malignant pleural mesothelioma, making it the standard first-line therapy in combination with a platinum-based drug such as cisplatin.¹

Pemetrexed works by inhibiting multiple folate-dependent enzymes that are essential for DNA synthesis and cell replication. Specifically, it targets thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). By disrupting these enzymes simultaneously, pemetrexed blocks the production of both purine and pyrimidine nucleotides — the building blocks of DNA — effectively starving rapidly dividing cancer cells of the materials they need to replicate.²

The approval of pemetrexed represented a major milestone in mesothelioma care. Prior to 2004, there was no FDA-approved systemic therapy for the disease, and patients had limited treatment options beyond supportive care and clinical trials. The landmark phase III trial led by Vogelzang and colleagues demonstrated that the combination of pemetrexed and cisplatin significantly improved both overall survival and quality of life compared to cisplatin alone — establishing the regimen that remains standard of care more than two decades later.¹

An essential component of pemetrexed therapy is vitamin supplementation. All patients must receive daily folic acid and periodic vitamin B12 injections beginning at least one week before the first dose. This supplementation dramatically reduces the incidence of severe hematologic and gastrointestinal toxicity without compromising anti-tumor efficacy — a discovery that was incorporated into the pivotal trial protocol after early safety analyses.³

Pemetrexed is administered as an intravenous infusion and is used in several treatment contexts for mesothelioma:¹

Standard First-Line Regimen

The established first-line protocol combines pemetrexed with cisplatin:²

• Pemetrexed — 500 mg/m² administered as a 10-minute intravenous infusion on Day 1 of each cycle
• Cisplatin — 75 mg/m² administered as an intravenous infusion approximately 30 minutes after pemetrexed on Day 1
• Cycle length — 21 days (3 weeks), typically for 4–6 cycles
• Pre-medications — Dexamethasone 4 mg orally twice daily for 3 days (day before, day of, day after infusion) to reduce skin reactions

Pivotal Clinical Trial Data

The Vogelzang trial (EMPHACIS), published in the Journal of Clinical Oncology in 2003, randomized 456 patients with unresectable malignant pleural mesothelioma:¹

• Median overall survival — 12.1 months (pemetrexed + cisplatin) vs. 9.3 months (cisplatin alone)
• Median time to progression — 5.7 months vs. 3.9 months
• Overall response rate — 41.3% vs. 16.7%
• Quality of life — Significant improvements in lung function and symptom scores in the combination arm

Alternative Combination With Carboplatin

For patients who cannot tolerate cisplatin due to renal impairment, hearing loss, or poor performance status, pemetrexed is frequently combined with carboplatin (AUC 5) on the same 21-day schedule. Retrospective data and phase II trials suggest comparable efficacy with a more favorable toxicity profile, though no randomized phase III comparison exists.⁴

Maintenance and Second-Line Use

Pemetrexed maintenance therapy — continuing pemetrexed alone after completion of the initial combination — has been studied in several trials. The CALGB 30901 trial showed that maintenance pemetrexed can extend progression-free survival. Pemetrexed rechallenge (restarting pemetrexed after a treatment break) is also used in patients who previously responded well and later progressed.³

The introduction of pemetrexed fundamentally changed survival expectations for mesothelioma patients:¹

• With pemetrexed + cisplatin — Median overall survival of 12.1 months, with approximately 50% of patients alive at one year
• Response rates — Approximately 40% of patients achieve a partial response, with additional patients experiencing stable disease
• Epithelioid histology — Patients with the epithelioid subtype tend to respond best, with median survival exceeding 13 months in some studies
• Combined with immunotherapy — Current trials are evaluating pemetrexed/platinum plus nivolumab or pembrolizumab, with early results suggesting further survival improvements

Managing the side effects of pemetrexed therapy requires proactive care and close communication with the oncology team:³

• Fatigue — The most commonly reported side effect, affecting up to 80% of patients. Moderate activity, structured rest periods, and nutritional support can help manage treatment-related fatigue
• Nausea and vomiting — Occurs in approximately 30–40% of patients, typically managed with anti-emetic medications (5-HT3 antagonists, dexamethasone) administered before and after infusion
• Myelosuppression — Low blood counts (neutropenia, anemia, thrombocytopenia) are common. Regular blood tests are required before each cycle. Dose delays or reductions may be necessary if counts are too low
• Skin rash — Pemetrexed can cause skin rashes, which are significantly reduced by dexamethasone pre-medication. Patients should report any new rash promptly
• Mucositis — Mouth sores and inflammation of the mucous membranes may occur. Good oral hygiene, gentle mouthwashes, and dietary modifications (avoiding spicy or acidic foods) can help
• Vitamin supplementation compliance — Daily folic acid (400–1000 mcg) and vitamin B12 injections (1000 mcg every 9 weeks) are mandatory throughout treatment and for 21 days after the last dose. These supplements reduce severe toxicity by 50–70% and must never be skipped
• Renal monitoring — Kidney function must be assessed before each cycle. Patients should maintain adequate hydration and report any decreased urine output